Literature DB >> 22209990

Macular function evaluated by focal macular electroretinograms after reduced fluence photodynamic therapy in eyes with polypoidal choroidal vasculopathy.

Shigeki Machida1, Tomoharu Nishimura, Kunifusa Tamada, Tomomi Harada, Daijiro Kurosaka.   

Abstract

The purpose of this study was to evaluate the macular function by measuring the focal macular electroretinograms (ERGs) recorded before and after reduced fluence photodynamic therapy (RFPDT) in patients with polypoidal choroidal vasculopathy (PCV). Eleven eyes of 11 patients with PCV were studied. Their ages ranged from 62 to 85 years with a mean of 74.7 ± 6.9 years. The exposure time for the RFPDT was reduced to 42 s, so that the total energy of the laser was approximately one-half that of the standard PDT. We measured the visual acuity, foveal thickness, and focal macular ERGs before and after the RFPDT. The follow-up period ranged from 13 to 34 months with a mean of 26 months after the treatment. A significant recovery of vision was seen even at 1 week after the RFPDT (P < 0.005), and the visual acuities improved gradually thereafter (P < 0.0005). The foveal thickness was significantly reduced at 1 week after the treatment (P < 0.005) and then continued to become significantly thinner with time (P < 0.0001). A slight recovery of the a- and b-wave amplitudes was seen postoperatively without a transient reduction in the amplitudes. The b-wave amplitude was significantly larger at 3 months after the treatment than at baseline (P < 0.05). Choroidal hypoperfusion did not develop 3 months postoperatively in the indocyanine green angiograms. Exudative changes recurred in 4 (27%) eyes after 1 year and in 9 (82%) eyes during the follow-up period. RFPDT provided short-term benefits in selected patients with PCV with small lesions. The macular function was retained after RFPDT without a transient decrease in visual function. Further study is needed to determine the long-term efficacy of RFPDT for eyes with PCV.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22209990     DOI: 10.1007/s10633-011-9307-9

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  17 in total

1.  [Criteria for diagnosis of polypoidal choroidal vasculopathy].

Authors: 
Journal:  Nippon Ganka Gakkai Zasshi       Date:  2005-07

2.  Subtype lesions of neovascular age-related macular degeneration in Chinese patients.

Authors:  Yan Liu; Feng Wen; Shizhou Huang; Guangwei Luo; Hong Yan; Zuhua Sun; Dezheng Wu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-04-04       Impact factor: 3.117

3.  Idiopathic polypoidal choroidal vasculopathy (IPCV).

Authors:  L A Yannuzzi; J Sorenson; R F Spaide; B Lipson
Journal:  Retina       Date:  1990       Impact factor: 4.256

4.  Influence of treatment parameters on selectivity of verteporfin therapy.

Authors:  Stephan Michels; Fabian Hansmann; Wolfgang Geitzenauer; Ursula Schmidt-Erfurth
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-01       Impact factor: 4.799

5.  Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy.

Authors:  R F Spaide; L A Yannuzzi; J S Slakter; J Sorenson; D A Orlach
Journal:  Retina       Date:  1995       Impact factor: 4.256

6.  Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics.

Authors:  Kenichiro Sho; Kanji Takahashi; Haruhiko Yamada; Mitsumasa Wada; Yoshimi Nagai; Tsuyoshi Otsuji; Maki Nishikawa; Yumiko Mitsuma; Yukari Yamazaki; Miyo Matsumura; Masanobu Uyama
Journal:  Arch Ophthalmol       Date:  2003-10

7.  Role of photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Eriko Akaza; Mitsuko Yuzawa; Yoko Matsumoto; Shiho Kashiwakura; Kyoko Fujita; Ryusaburo Mori
Journal:  Jpn J Ophthalmol       Date:  2007-08-03       Impact factor: 2.447

8.  Correlation between focal macular electroretinograms and angiographic findings after photodynamic therapy.

Authors:  Kohei Ishikawa; Mineo Kondo; Yasuki Ito; Masato Kikuchi; Hiroaki Nishihara; Chang-Hua Piao; Tadasu Sugita; Hiroko Terasaki
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-05       Impact factor: 4.799

9.  Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy.

Authors:  Eriko Akaza; Ryusaburo Mori; Mitsuko Yuzawa
Journal:  Retina       Date:  2008-05       Impact factor: 4.256

10.  One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Ayana Yamashita; Fumio Shiraga; Chieko Shiragami; Aoi Ono; Kaori Tenkumo
Journal:  Am J Ophthalmol       Date:  2009-12-30       Impact factor: 5.258

View more
  2 in total

1.  One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Madoka Sakurai; Takayuki Baba; Masayasu Kitahashi; Hirotaka Yokouchi; Mariko Kubota-Taniai; Guzel Bikbova; Toshiyuki Oshitari; Shuichi Yamamoto
Journal:  Clin Ophthalmol       Date:  2014-01-28

2.  Microperimetry and multimodal imaging in polypoidal choroidal vasculopathy.

Authors:  Jennifer H Acton; Ken Ogino; Yumiko Akagi; John M Wild; Nagahisa Yoshimura
Journal:  Sci Rep       Date:  2018-10-25       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.